Financings roundup

June 2011
Medical Device Daily;6/27/2011, Vol. 15 Issue 118, p3
The article reports on a closing by Avita Medical of the placement of its capital raising deal disclosed on May 17, 2011.


Related Articles

  • AVITA GETS AU$2M FROM US MILITARY TO SPEED DEVICE APPROVAL.  // Worldwide Biotech;Jul2009, Vol. 21 Issue 7, p2 

    The article reports that $1.45 million have been given by the U.S. Armed Forces Institute of Regenerative Medicine (AFIRM) to Avita Medical Ltd. The money will be used to speed up the approval of the ReCell Autologous Cell Harvesting device of Avita in the U.S. It is noted that the device will...

  • Avita Medical Announces Free Issuance Period for Conversion of AVMXF Shares to AVMXY ADRs.  // Biomedical Market Newsletter;6/7/2012, Vol. 21, p1 

    The article offers information on the free issuance period announced by Avita Medical Ltd. (AVMXF) through the Bank of New York Mellon Corp. for conversion of AVMXF shares into American Depository Receipts (ADRs). A bundle of 20 ordinary shares is present in each AVMXY ADR which helps in...

  • Avita introduces ReCell in Arabian Peninsula.  // Medical Device Daily;5/27/2011, Vol. 15 Issue 103, p2 

    The article reports on the introduction by Avita Medical of its ReCell Spray-On-Skin to the health care market in the Arabian Peninsula.

  • Skin trade: partnership seeks greater understanding of wound healing device.  // Engineer (Online Edition);8/20/2015, p1 

    The article reports on the partnership of Huddersfield University in England and regenerative medicine company Avita Medical Ltd. to explore the mechanism of Regenerative Epithelial Suspension (RES) to better understand its ability to treat cutaneous anomalies including burns.

  • Avita enters into j-v to expand sales of ReCell.  // Medical Device Daily;9/12/2011, Vol. 15 Issue 173, p8 

    The article reports that regenerative medicine company Avita Medical entered into a partnership with Kuwait-based MENA United to sell its ReCell Spray-On Skin regenerative product in Egypt, Bahrain, Syria and the other countries in the Middle East and North Africa region.

  • Study Demonstrates That Avita Medical's ReCell(r) Spray-On Skin(tm) "Has Potentially Broad Application to the Healing of Acute and Chronic Wounds".  // Biomedical Market Newsletter;5/7/2011, p92 

    The article evaluates ReCell® Spray-On Skin™, from Avita Medical Ltd., a regenerative medicine that been proven with potential broad application in treating acute and chronic wounds.

  • Avita Medical Expands Sales and Marketing Operations in Europe.  // Biomedical Market Newsletter;5/7/2011, p390 

    The article reports on the move of the regenerative medicine company Avita Medical Ltd. to expand its sales and marketing operations in Europe. It mentions that the company had aimed to work closely with highly regarded surgeons in Russia, the Netherlands and Portugal to develop a group of key...

  • Avita Medical Launches ReCell Spray-On-Skin Treatment of Venous Ulcers.  // Biomedical Market Newsletter;10/17/2011, Vol. 21, p265 

    The article reports on the launching of ReCell Spray-On Skin from Avita Medical Ltd. for the treatment of chronic leg ulcers. It states that area, depth, volume and extent of ulcers prior to and post-treatment with ReCell were objectively quantified using a 3D laser scanner. It notes that...

  • People in the News.  // Medical Device Daily;8/29/2011, Vol. 15 Issue 164, p4 

    The article announces the appointment of Michael Mendicino as the research and development (R&D) program manager of Avita Medical in Northridge, California and the addition of Trey Martin as the director of dermatopathology for Poplar Healthcare in Memphis, Tennessee.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics